Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis : workshop summary /

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resist...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autores principales: Nicholson, Anna (Autor), English, Rebecca A. (Autor), Guenther, Rita S. (Autor), Claiborne, Anne B. (Autor)
Autores Corporativos: Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation (sponsoring body.), Workshop on Global Drug Supply Chain for Secondline Anti-tuberculosis Drugs
Formato: Electrónico Congresos, conferencias eBook
Idioma:Inglés
Publicado: Washington, D.C. : National Academies Press, [2013]
Temas:
Multidrug-resistant tuberculosis > Prevention > Congresses.
Business logistics > Congresses.
International cooperation > Congresses.
Tuberculosis, Multidrug-Resistant > drug therapy
Extensively Drug-Resistant Tuberculosis > drug therapy
Internationality
Logistique (Organisation) > Congrès.
Coopération internationale > Congrès.
POLITICAL SCIENCE > Public Policy > Social Security.
POLITICAL SCIENCE > Public Policy > Social Services & Welfare.
Business logistics
International cooperation
Congress
proceedings (reports)
Conference papers and proceedings
Conference papers and proceedings.
Actes de congrès.
Acceso en línea:Texto completo
Descripción
Sumario:To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)--a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)--face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high-quality medicines to more of the people who need them.
Notas:Title from PDF title page.
Descripción Física:1 online resource (xvii, 152 pages) : illustrations
Bibliografía:Includes bibliographical references.
ISBN:9780309265980
0309265983
9780309265966
0309265967

Ejemplares similares